TRAW

SEC source: 0000919574-19-006024 · ownership.xml · nonDerivative · entry 1

ARMISTICE CAPITAL, LLC · CIK 0001601086 · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner

Boyd Steven · CIK 0001706140 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,702

F1 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-19-000785 · onconova_fm4sept202019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 670,331

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000781 · onconova_fm4sept182019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 745,450

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0001567619-19-018586 · doc1.xml · nonDerivative · entry 5

683 Capital Management, LLC · CIK 0001404574 · Former 10% Owner

683 Capital Partners, LP · CIK 0001380126 · 10% owner

Zweiman Ari · CIK 0001612431 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 683 Capital Partners, LP

Disclosed balance after: 460,000

F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that no longer collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners.

SEC source: 0001567619-19-018586 · doc1.xml · nonDerivative · entry 4

683 Capital Management, LLC · CIK 0001404574 · Former 10% Owner

683 Capital Partners, LP · CIK 0001380126 · 10% owner

Zweiman Ari · CIK 0001612431 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 683 Capital Partners, LP

Disclosed balance after: 461,533

F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that no longer collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners.

SEC source: 0001567619-19-018586 · doc1.xml · nonDerivative · entry 3

683 Capital Management, LLC · CIK 0001404574 · Former 10% Owner

683 Capital Partners, LP · CIK 0001380126 · 10% owner

Zweiman Ari · CIK 0001612431 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 683 Capital Partners, LP

Disclosed balance after: 581,533

F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that no longer collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners.

SEC source: 0001567619-19-018586 · doc1.xml · nonDerivative · entry 2

683 Capital Management, LLC · CIK 0001404574 · Former 10% Owner

683 Capital Partners, LP · CIK 0001380126 · 10% owner

Zweiman Ari · CIK 0001612431 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 683 Capital Partners, LP

Disclosed balance after: 754,865

F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that no longer collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners.

SEC source: 0001567619-19-018586 · doc1.xml · nonDerivative · entry 1

683 Capital Management, LLC · CIK 0001404574 · Former 10% Owner

683 Capital Partners, LP · CIK 0001380126 · 10% owner

Zweiman Ari · CIK 0001612431 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By 683 Capital Partners, LP

Disclosed balance after: 848,151

F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that no longer collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners.

SEC source: 0000905718-19-000775 · onconova_fm4sept112019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 795,445

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000773 · onconova_fm4sept092019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 796,692

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000753 · onconova_fm4sept052019.xml · nonDerivative · entry 2

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 797,092

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000753 · onconova_fm4sept052019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 802,107

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0001179110-19-008871 · edgar.xml · derivative · entry 1

GROOPMAN JEROME · CIK 0001218853 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-19-008868 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-19-008869 · edgar.xml · derivative · entry 1

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-19-008867 · edgar.xml · derivative · entry 1

MEHTA VIREN · CIK 0001238969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-19-008866 · edgar.xml · derivative · entry 1

Reddy E Premkumar · CIK 0001580071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-19-008865 · edgar.xml · derivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0000905718-19-000596 · onconova_fm4jul92019.xml · nonDerivative · entry 2

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 802,507

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000596 · onconova_fm4jul92019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 805,249

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000579 · onconova_fm4jun252019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 813,434

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-19-000557 · onconova_fm4jun252019.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 814,892

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0001179110-19-004834 · edgar.xml · derivative · entry 1

Maniar Manoj · CIK 0001642906 · SVP - Product Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2028-12-12

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-012642 · edgar.xml · derivative · entry 1

Woodman Richard Charles · CIK 0001758427 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2028-11-05

F1 · derivative.exercise_date: These options vest over 4 years. 25% on the first anniversary of the grant date and the remainder in 36 equal monthly installments over the last 3 years.

SEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 4

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust

Disclosed balance after: 5,731,116.738

F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor.

F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust.

SEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 3

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust

Disclosed balance after: 5,761,116

F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor.

F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust.

SEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 2

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust

Disclosed balance after: 5,791,116

F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor.

F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust.

SEC source: 0001104659-18-054173 · a4.xml · nonDerivative · entry 1

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Michael and Jane Hoffman 2018 Descendants Trust

Disclosed balance after: 5,811,116

F2 · balance_after: Includes (i) 19,951 options to purchase shares of Common Stock of the Issuer, which are immediately exercisable or will be exercisable within 60 days of the date hereof; (ii) 5,700,836.738 shares of Common Stock held by the Michael and Jane Hoffman 2018 Descendants Trust, of which Mr. Hoffman is donor (which includes 2,211,765 shares of Common Stock issuable upon the exercise of warrants for 55,294.125 shares of Series B Preferred Stock that convert into shares of Common Stock and 396,633 shares of Common Stock issuable upon the exercise of warrants, all of which are immediately exercisable or exercisable within 60 days hereof); and (iii) 8,453 shares of Common Stock held by the Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust), of which Mr. Hoffman is donor.

F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. The reporting person is a general agent of the trust.

SEC source: 0001179110-18-010016 · edgar.xml · derivative · entry 1

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-010015 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-010013 · edgar.xml · derivative · entry 1

MEHTA VIREN · CIK 0001238969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-010014 · edgar.xml · derivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-010010 · edgar.xml · derivative · entry 1

Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,950

Underlying: Common Stock · 384,950 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

SEC source: 0001179110-18-010012 · edgar.xml · derivative · entry 1

Reddy E Premkumar · CIK 0001580071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-010011 · edgar.xml · derivative · entry 1

GROOPMAN JEROME · CIK 0001218853 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-010009 · edgar.xml · derivative · entry 1

Kumar Ramesh · CIK 0001580074 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,065,600

Underlying: Common Stock · 1,065,600 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

SEC source: 0001179110-18-010008 · edgar.xml · derivative · entry 1

Fruchtman Steven M · CIK 0001631251 · President, Chief Medical Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

SEC source: 0001179110-18-010007 · edgar.xml · derivative · entry 1

Maniar Manoj · CIK 0001642906 · SVP - Product Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

SEC source: 0001179110-18-007740 · edgar.xml · nonDerivative · entry 1

Bienen Henry S · CIK 0001304250 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,724

SEC source: 0001179110-18-006018 · edgar.xml · derivative · entry 4

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Michael and Jane Hoffman 2013 Descendants Trust

Disclosed balance after: 2,211,765

Underlying: Series B Convertible Preferred Stock · 55,294.13 shares

Expires not disclosed

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

F3 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.

SEC source: 0001179110-18-006018 · edgar.xml · nonDerivative · entry 1

Hoffman Michael B · CIK 0001290208 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Michael and Jane Hoffman 2013 Descendants Trust

Disclosed balance after: 3,192,438

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F3 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.

SEC source: 0001179110-18-006019 · edgar.xml · derivative · entry 2

Reddy E Premkumar · CIK 0001580071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,350

Underlying: Series B Convertible Preferred Stock · 7,058.75 shares

Expires not disclosed

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

SEC source: 0001179110-18-006019 · edgar.xml · nonDerivative · entry 1

Reddy E Premkumar · CIK 0001580071 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 668,182

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

SEC source: 0001179110-18-006015 · edgar.xml · derivative · entry 2

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,100

Underlying: Series B Convertible Preferred Stock · 1,177.5 shares

Expires not disclosed

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

SEC source: 0001179110-18-006015 · edgar.xml · nonDerivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,110

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

SEC source: 0001179110-18-006013 · edgar.xml · derivative · entry 2

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,900

Underlying: Series B Convertible Prefered Stock · 1,472.5 shares

Expires not disclosed

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

SEC source: 0001179110-18-006013 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,221

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

SEC source: 0001140361-18-020866 · doc1.xml · nonDerivative · entry 1

683 Capital Management, LLC · CIK 0001404574 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By 683 Capital Partners, LP

Disclosed balance after: 14,503,169

F1 · security: This Form 4 is filed jointly by 683 Capital Management, LLC ("683 Management"), 683 Capital Partners, LP ("683 Partners") and Ari Zweiman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Represents securities held directly by 683 Partners. 683 Management is the investment manager of 683 Partners. Ari Zweiman is the Managing Member of 683 Management. As a result, each of 683 Management and Ari Zweiman may be deemed to beneficially own the securities held by 683 Partners.

SEC source: 0000905718-18-000415 · onconova_fm4apr272018.xml · derivative · entry 2

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 10,147,058

Underlying: Series B Preferred Stock · 253,677 shares

Expires not disclosed

F2 · derivative.exercise_price: Each warrant ("Warrant") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). Onconova Therapeutics, Inc. (the "Company") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the "Charter Amendment") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock.

F2 · price: Each warrant ("Warrant") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). Onconova Therapeutics, Inc. (the "Company") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the "Charter Amendment") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock.

F4 · price: 10,147,058 Units purchased for $0.425 per Unit. Each Unit consists of one share of Common Stock and one Warrant.

F3 · derivative.expiration_date: The Warrants are exercisable immediately and will expire on the eighteen (18) month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that the Charter Amendment has been filed with the Secretary of State of the State of Delaware.

F2 · derivative.underlying_shares: Each warrant ("Warrant") is exercisable into 0.025 share of Series B Convertible Preferred Stock, par value $0.01 per share ("Preferred Stock") at an exercise price of $0.425 per 0.025 share of Preferred Stock. Each 0.025 share of Preferred Stock will be convertible into one share of common stock, par value $0.01 per share (the "Common Stock"). Onconova Therapeutics, Inc. (the "Company") does not currently have a sufficient number of authorized shares of Common Stock to cover the shares issuable upon the conversion of the Preferred Stock. As a result, before any shares of Preferred Stock can be converted, the Company must obtain stockholder approval of an amendment (the "Charter Amendment") to its certificate of incorporation, as amended, to sufficiently increase its authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock.

F3 · derivative.underlying_shares: The Warrants are exercisable immediately and will expire on the eighteen (18) month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that the Charter Amendment has been filed with the Secretary of State of the State of Delaware.

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.

SEC source: 0000905718-18-000415 · onconova_fm4apr272018.xml · nonDerivative · entry 1

TYNDALL CAPITAL PARTNERS L P · CIK 0001219314 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 12,244,080

F1 · ownership.nature: Tyndall Capital Partners, L.P. ("Tyndall Capital") is the general partner of Tyndall Partners, L.P. ("Tyndall"), and possesses the sole power to vote and the sole power to direct the disposition of all securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any.